CoChat

Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.

Bowers, Cyril Y., Granda, Ramona, Mohan, Subburaman, Kuipers, Jonathan, Baylink, David, Veldhuis, Johannes D. · 2004 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 108 of the 115 references it cites were found in a registry or an index.

Abstract

We test the interlinked hypotheses that in healthy older adults: 1). i.v. injection of GH-releasing peptide-2 (GHRP-2) and GHRH synergizes more in aging women than men; 2). sc infusion of both GHRP-2 (1 microg/kg.h = 1) and GHRH (1, 3, or 10) for 24 h augments GH secretion more than either agonist alone; and 3). continuous sc delivery of GHRP-2 (1) for 30 d stimulates daily GH secretion and IGF-I, IGF-binding protein-3 (IGFBP-3), and IGFBP-5. Acute two-peptide synergy was 3-fold greater in young (n = 16) than older volunteers (n = 17; P < 0.025) and was 2.3-fold higher in elderly women than men (P < 0.025). The 24-h infusion of GHRP-2 (1) combined with GHRH (3 or 10) in men and with GHRH (10) in women drove GH secretion more than GHRH alone (P <or= 0.024). In the entire cohort (n = 11), GHRP-2/GHRH (1/10) stimulated GH secretion more than either GHRP-2 (1; P = 0.021) or GHRH (10; P = 0.012). The 30-d delivery of GHRP-2 (1; n = 17 subjects): 1). stimulated pulsatile, rhythmic, and entropic GH secretion by more than 3-fold on d 1 and more than 1.8-fold on d 14 and 30 (each P < 0.001 vs. saline); 2). elevated IGF-I to a stable plateau on d 1, 14, and 30 (P < 0.025 vs. baseline); and 3). increased IGFBP-3 (P < 0.01) and IGFBP-5 (P < 0.025) on d 14 and/or 30. Safety screening tests remained normal. In summary, in healthy elderly women and men: 1). acute synergy of GHRP-2 and GHRH is greater in the female; 2). 24-h combined GHRP-2 and GHRH drive is more effective than either agonist alone; and 3). 30-d stimulation with GHRP-2 sustains a physiologically activated somatotropic axis. We conclude that age, gender, stimulus duration, and secretagogue combination determine acute, intermediate, and extended responses of the somatotropic axis in the older adult.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-031799

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 108 references

Research works printed but not linked: 4

  1. Bowers, 1998, Synergistic release of growth hormone by GHRP and GHRH: scope and implication, In: Bercu BB, Walker RF, eds. Growth hormone secretagogues in clinical practice. New York: Marcel Dekker;, 1
  2. Van den Berghe, 1997, The somatotropic axis in critical illness: effects of continuous GHRH and GHRP-2 infusion., J Clin Endocrinol Metab, 82, 590
  3. Bowers, 2002, New insight into the control of growth hormone secretion, In: Kleinberg DL, Clemmons DR, eds. Central and peripheral mechanisms in pituitary disease. Bristal: BioScientifica;, 163
  4. Maccario, 2002, Impact of two or three daily subcutaneous injections of hexarelin, a synthetic GH secretagogue (GHS), on 24-hour GH, prolactin, ACTH and cortisol secretion in the human., Eur J Endocrinol, 146, 311

Cited by

See all 57

Metadata

Authors
Bowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., & Veldhuis, J. D.
Affiliations
  • Tulane University (US)
  • Tulane University Health Sciences Center (C.Y.B., R.G.), New Orleans, Louisiana 70112
  • Loma Linda University (US)
  • Mayo Clinic (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-05-01
Volume
89
Issue
5
Pages
2290-2300
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2016761387
Cited by
57
References
115
Citations by year
2025: 1 · 2023: 1 · 2021: 1 · 2019: 1 · 2017: 1 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 5
FWCI
5.58
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG-19695, R01-AG14799, R01AG014799)
  • National Center for Research Resources (RR-00585, M01-RR-05096, M01RR000585, M01RR005096)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
pulsatile growth hormone secretion, GHRP-2, growth hormone-releasing hormone, growth hormone, insulin-like growth factor I, IGF binding protein-3, IGF binding protein-5, aging, sex differences, continuous subcutaneous infusion, peptide synergy, older adults, growth hormone therapy, IGF-I bioactivity, IGF-I/IGFBP-3 ratio
MeSH terms
Aged, Drug Administration Schedule, Female, Humans, Infusion Pumps, Injections, Intravenous, Injections, Subcutaneous, Insulin-Like Growth Factor I, Male, Middle Aged, Oligopeptides, Osmolar Concentration, Pulsatile Flow, Reference Values, Cohort Studies, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor Binding Protein 5, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. https://app.cochat.ai/papers/10.1210/jc.2003-031799
The paper
Bowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., & Veldhuis, J. D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-031799

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.